An effective HIV vaccine: A combination of humoral and cellular immunity?

Current HIV Research

Volumn 8, Issue 6, 2010, Pages 441-449

  Benmira, Sihame ^a,b   Bhattacharya, Vish ^b   Schmid, Matthias L ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

AIDS; Antiretroviral drugs; Cellular immunity; HIV vaccine; Humoral immunity; Prime boost vaccine

Indexed keywords

ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE SYSTEM; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; SEXUAL BEHAVIOR; T LYMPHOCYTE; TREATMENT RESPONSE; VACCINE PRODUCTION; VIRAL GENETICS; VIRUS MORPHOLOGY; VIRUS PATHOGENESIS; VIRUS TRANSMISSION;

EID: 78249257289     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210793499286     Document Type: Article

References (26)

1. UNAIDS. AIDS epidemic update: December 2008. Available at: http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_ en.pdf. (Accessed on May 1, 2010).
2. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191(5): 654-65.
3. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194(12): 1661-71.
4. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372(9653): 1881-93.
5. NIAID. STATEMENT: Immunizations Are Discontinued in Two HIV Vaccine Trials. Available at: http://www.niaid.nih.gov/news/ newsreleases/2007/pages/step_statement.aspx. (Accessed on: April 1, 2010).
6. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23): 2209-20.
7. Bajko MS. New trial of HIV vaccine in gay men begins. Available at: http://www.edgeboston.com/index.php?ch=news&sc=&sc2=ne ws&sc3=&id=97152. (Accessed on April 2, 2010).
8. Burgers WA, Williamson C. The challenges of HIV vaccine development and testing. Best Pract Res Clin Obstet Gynaecol 2005; 19(2): 277-91.
9. Singh M. No vaccine against HIV yet--are we not perfectly equipped? Virol J 2006; 3: 60.
10. Kim T-A, Avraham HK, Koh Y-H, Jiang S, Park I-W, Avraham S. HIV-1 Tat-mediated apoptosis in human brain microvascular endothelial cells. J Immunol 2003; 170(5): 2629-37.
11. Maccarrone M, Navarra M, Corasaniti MT, Nistico G, Finazzi Agro A. Cytotoxic effect of HIV-1 coat glycoprotein gp120 on human neuroblastoma CHP100 cells involves activation of the arachidonate cascade. Biochem J 1998; 333(Pt 1): 45-9.
12. Mordelet E, Altmeyer R, Girard M, Vidal C. HIV-1 gp120: expression and subcellular localisation in macrophages/microglia in vitro and in vivo in the rat brain. Neuroscience of HIV Infection. J Neurovirol 1998; 4: 360.
13. Briant L, Robert-Hebmann V, Sivan V, Brunet A, Pouyssegur J, Devaux C. Involvement of extracellular signal-regulated kinase module in HIV-mediated CD4 signals controlling activation of nuclear factor-kappa B and AP-1 transcription factors. J Immunol 1998; 160(4): 1875-85.
14. Popik W, Hesselgesser JE, Pitha PM. Binding of human immunodeficiency virus type 1 to CD4 and CXCR4 receptors differentially regulates expression of inflammatory genes and activates the MEK/ERK signaling pathway. J Virol 1998; 72(8): 6406-13.
15. Robinson HL. HIV/AIDS vaccines: 2007. Int J Clin Pharmacol Ther 2007; 82(6): 686-93.
16. Graham BS, Mascola JR. Lessons from failure--preparing for future HIV-1 vaccine efficacy trials. J Infect Dis 2005; 191(5): 647-9.
17. Tonks A. Quest for the AIDS vaccine. BMJ 2007; 334(7608): 1346-8.
18. Sullivan PS, Kilmarx PH, Peterman TA, et al. Male circumcision for prevention of HIV transmission: what the new data mean for HIV prevention in the United States. PLoS Med 2007; 4(7): e223.
19. Gray G. Interim efficacy analysis of HVTN 503/Phambili: a phase IIb test of concept trial of the MRK Ad5 HIV-1 gag/pol/nef vaccine conducted in HIV-1 uninfected adults in South Africa. AIDS Vaccine 2009. Paris, France (2009).
20. Letvin NL. Progress and obstacles in the development of an AIDS vaccine. Immunology 2006; 6(12): 930-9.
21. Nitayaphan S, Pitisuttithum P, Karnasuta C, et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 2004; 190(4): 702-6.
22. US National Institute of Health. Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial. Available at: http://clinicaltrials. gov/ct2/show/NCT00337181. (Accessed on: April 1, 2010).
23. Russell ND, Graham BS, Keefer MC, et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007; 44(2): 203-12.
24. U.S. National Institute of Health. Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men. Available at: http://clinicaltrials.gov/ct2/show/NCT00865566 (Accessed on: April 2, 2010).
25. Will there be an HIV vaccine in the next 10 years? Nat Med 2007; 13(5): 518-519.
26. Markel H. The search for effective HIV vaccines. N Engl J Med 2005; 353(8): 753-7.